Key result
Heart failure trials severely underrepresent African American patients, highlighting critical gaps in tailored pharmacotherapy.
Why the study?
The authors aimed to review published literature evaluating pharmacotherapy treatment approaches for chronic heart failure, notably as it relates to African American patients.
What are the current gaps in evidence regarding optimal pharmacotherapy for chronic heart failure in African American patients?
What are the current gaps in evidence regarding optimal pharmacotherapy for chronic heart failure in African American patients?
This review highlights critical gaps in the evidence base for treating chronic heart failure in African Americans, emphasizing the need for targeted studies to inform consensus guidelines.
Answers are grounded in this paper and cite their sources.
Does not support altering standard HF therapies in African Americans yet; leaves open optimization via dedicated trials.
BACKGROUND: Our aim was to review the published literature evaluating treatment approaches for chronic heart failure (HF), notably as it relates to African American patients. METHOD: We undertook a comprehensive database search (1986-2017) of PubMed, EMBASE, and Ovid/MEDLINE utilizing terms 'African American', 'black', 'chronic heart failure', 'heart failure', 'medication', 'chronic therapy', and 'clinical trials'. Additional notable studies were obtained from ClinicalTrials.gov . Studies published in English that examine treatment modalities of chronic HF in African American and non-African American patients were included. RESULTS: Examples of current gaps worthy of investigation include whether to maximize thiazides and calcium-channel blockers prior to adding renin-angiotensin system (RAS) inhibitors or beta blockers in HF with preserved ejection fraction; whether hydralazine/isosorbide dinitrate (ISDN) should be initiated during earlier HF stages; whether to prioritize hydralazine/ISDN over other agents such as RAS inhibitors; varying response of African Americans to different agents within drug classes; and the role of mineralocorticoid receptor antagonists. CONCLUSION: Further studies are needed in order for consensus guidelines to clarify how best to treat this population.
No takes yet. Share an insight, caveat, or question.
Tillman et al. (2019) conducted a review in Chronic heart failure in African Americans. Heart failure pharmacotherapy (e.g., hydralazine/isosorbide dinitrate, RAS inhibitors, beta blockers, MRAs) vs. Placebo or standard therapy across reviewed trials was evaluated. African American patients are severely underrepresented in pivotal heart failure trials and may have varying responses to standard therapies, underscoring the need for dedicated, adequately powered studies to optimize pharmacotherapy in this population.
Synapse has enriched 10 related papers. Consider them for comparative context: